I saw many quite suprised that ROIV didn't rally after the Roche drug acquisition annoucement. Yet another example of (soon to be) too much cash on the balance sheet. One could also say the same thing about BUR and the YPF news. Though yet to be collected, a windfall is all but guarenteed. In Burfords case the stock popped for a short pe…
I saw many quite suprised that ROIV didn't rally after the Roche drug acquisition annoucement. Yet another example of (soon to be) too much cash on the balance sheet. One could also say the same thing about BUR and the YPF news. Though yet to be collected, a windfall is all but guarenteed. In Burfords case the stock popped for a short period of time and settled back to where ot traded pre-YPF win. I guess having a crystal clear capital allocation framework is important. I'm not sure what the lesson is but interesting to think about
I saw many quite suprised that ROIV didn't rally after the Roche drug acquisition annoucement. Yet another example of (soon to be) too much cash on the balance sheet. One could also say the same thing about BUR and the YPF news. Though yet to be collected, a windfall is all but guarenteed. In Burfords case the stock popped for a short period of time and settled back to where ot traded pre-YPF win. I guess having a crystal clear capital allocation framework is important. I'm not sure what the lesson is but interesting to think about
these are some great examples that I'm very familiar with and agree are well worth thinking about!